



**U.S. Department of Health & Human Services
Office of Inspector General**

Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices

OEI-03-18-00120

August 2018

oig.hhs.gov

Suzanne Murrin
Deputy Inspector General






Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices

What OIG Found

- The Centers for Medicare & Medicaid Services (CMS) lowered Part B reimbursement for 16 drugs on the basis of 2016 data.
- CMS's price-substitution policy saved Medicare and its beneficiaries \$13.1 million over 1 year.
- Medicare and its beneficiaries could have saved up to an additional \$2.7 million over 1 year if CMS implemented a more expansive price-substitution policy that, for example, allowed substitution for drugs that exceeded the 5-percent threshold in a single quarter.

Exhibit 1: Results of the Medicare Part B Price-Substitution Policy



Source: OIG analysis of average sales price (ASP) and average manufacturer price (AMP) data from 2016

What OIG Recommends

Because of the potential for savings to Medicare beneficiaries and the program, OIG recommends that CMS expand the price-substitution policy. CMS did not concur with the recommendation, instead stating that as additional data become available and as it continues to gain experience with the price-substitution policy, it will consider further changes as necessary. OIG recognizes that CMS, in setting policy for payment substitution, needs to balance safeguarding access to drugs and ensuring that Medicare and its beneficiaries do not overpay for drugs. To provide greater flexibility and achieve this continued balance, any future expansion of the payment-substitution policy could contain a provision that would prevent a price substitution when there are indications that the substitution amount is below the provider acquisition costs.

Why OIG Did This Review

When Congress established average sales price (ASP) as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and limiting potentially excessive payment amounts. The Social Security Act mandates that the Office of Inspector General (OIG) compare ASPs with average manufacturer prices (AMPs). If OIG finds that the ASP for a drug exceeds the AMP by a certain percentage (currently 5 percent), the Act directs the Secretary of Health and Human Services to substitute the ASP-based payment amount with a lower calculated rate. Through regulation, CMS outlined that it would make this substitution only if the ASP for a drug exceeds the AMP by 5 percent in the previous 2 quarters or 3 of the previous 4 quarters.

Over the last decade, OIG has produced annual reports aggregating the results of our mandated quarterly ASP-to-AMP comparisons. This annual report quantifies the savings to Medicare and its beneficiaries that are a direct result of CMS's price-substitution policy based on 2016 ASPs, and this report also offers recommendations for achieving additional savings.

How OIG Did This Review

To determine the effects of the price-substitution policy, we calculated the difference between ASP-based payment and AMP-based payment for each drug with a price substitution. We then applied this difference to the Medicare utilization for each of these drugs. To account for a 3-quarter lag between the reporting of pricing data and the application of price substitutions, we used drug utilization data for the fourth quarter of 2016 through the third quarter of 2017 to calculate the savings based on 2016 data.

TABLE OF CONTENTS

BACKGROUND	1
Methodology	3
<hr/>	
FINDINGS	
CMS’s price-substitution policy saved Medicare and its beneficiaries \$13.1 million over 1 year	5
Expanding the price-substitution criteria could have generated up to \$2.7 million in additional savings for Medicare and its beneficiaries	6
<hr/>	
CONCLUSION AND RECOMMENDATIONS	
Expand the price-substitution policy	7
Agency Comments and OIG Response	8
<hr/>	
APPENDIXES	
A: Detailed Methodology	9
B: Agency Comments	10
<hr/>	
ACKNOWLEDGMENTS	12

BACKGROUND

Objectives

1. To quantify the Medicare savings resulting from price substitutions—based on 2016 average sales prices (ASPs)—for certain Part B-covered drugs.
2. To estimate the financial impact of expanding the Centers for Medicare & Medicaid Services' (CMS) criteria for price substitution.

Drug Pricing Terms

Manufacturer's Average Sales Price (ASP)

In general, the manufacturer's ASP for a unit of drug that is sold is defined as the manufacturer's sales of a drug to all purchasers in the United States in a calendar quarter divided by the total number of units of the drug sold by the manufacturer in that same quarter.

Average Manufacturer Price (AMP)

In general, AMP is defined as the average price paid to the manufacturer for the drug in the United States by (1) wholesalers for drugs distributed to retail community pharmacies and (2) retail community pharmacies that purchase drugs directly from the manufacturer.

National Drug Code (NDC)

An NDC is a code used to identify a drug based on its manufacturer, product, and package size.

Healthcare Common Procedure Coding System (HCPCS) Code

A HCPCS code is a standardized billing code that is used primarily to identify products, supplies, and other services. A HCPCS code specifies the name and the amount of the drug and may represent one or more NDCs.

When Congress established ASP as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and adjusting ASP-based payments in certain situations. Specifically, the Social Security Act (the Act) mandates that the Office of Inspector General (OIG) compare ASPs with average manufacturer prices (AMPs).¹ If OIG finds that the ASP for a drug exceeds the AMP by a certain percentage (currently 5 percent), the Act directs the Secretary of Health and Human Services (after being notified by OIG) to substitute the payment amount with the lesser of the widely available market price (if any) or 103 percent of the AMP.^{2, 3}

Payments for Prescription Drugs Under Medicare Part B

Medicare Part B covers a limited number of outpatient prescription drugs. These drugs are usually administered in a physician's office or other outpatient setting and include, for example, drugs used to treat cancer. To obtain reimbursement for Part B drugs, health care providers submit claims to Medicare contractors using Healthcare Common Procedure Coding System (HCPCS) codes. (Hereinafter in this report, we refer to HCPCS codes as "drugs."⁴)

CMS calculates the payment amount for these drugs using information provided by manufacturers. Certain manufacturers must provide CMS quarterly with the ASP and volume of sales for each of their National Drug Codes (NDCs).^{5, 6} CMS then calculates an ASP-based payment amount for the drug; this amount includes all of the NDCs associated with the drug.⁷ Under the ASP pricing methodology, the Medicare reimbursement for most

¹ Section 1847A(d)(2)(B) of the Social Security Act (the Act).

² Section 1847A(d)(3) of the Act.

³ Pursuant to § 1847A(d)(3)(B)(ii) of the Act, the threshold percentage has been maintained at 5 percent.

⁴ A HCPCS code for a drug defines the drug name and the amount of the drug represented by the HCPCS code but does not specify the manufacturer or package size.

⁵ Section 1927(b)(3) of the Act.

⁶ See sidebar for the definition of an NDC.

⁷ Section 1847A(c) of the Act. Certain types of sales are exempted from ASP, and ASP is net of any price concessions (with limited exceptions).

Part B drugs is equal to 106 percent of the volume-weighted ASP for the drug.⁸ However, under sequestration legislation, Medicare's portion of the payment amount for most drugs is reduced by 2 percent.⁹

Quarterly reimbursement amounts are not based on current quarter data because there is a 2-quarter lag between the sales period for which ASPs are reported and the effective date of the reimbursement amounts. For example, manufacturers' ASPs from the first quarter of 2016 were used to establish reimbursement amounts for the third quarter of 2016.

Manufacturer Reporting of AMPs

In addition to providing quarterly ASPs, certain manufacturers must provide CMS quarterly with the AMP for each of their NDCs.¹⁰ The AMP is generally calculated as a weighted average of prices for all of a manufacturer's package sizes of a drug and is reported for the lowest identifiable quantity of the drug, e.g., 1 milliliter, one tablet, one capsule.

AMP-Based Price Substitutions

Through regulation, CMS established the criteria under which it would implement a price substitution for a drug. CMS may substitute 103 percent of the AMP for the ASP-based reimbursement amount when OIG identifies a drug that exceeds the 5-percent threshold in the previous 2 quarters or 3 of the previous 4 quarters.¹¹ CMS implemented the AMP substitution policy in April 2013. Because CMS believes that comparisons based on partial AMP data may not adequately reflect market trends, the agency will consider lowering reimbursement amounts only when corresponding AMP data is available for each of the NDCs used to determine the published reimbursement amount for a drug.¹² To prevent the price-substitution policy from inadvertently raising Medicare reimbursement amounts, CMS does not substitute prices when the substituted amount is greater than the ASP-based payment amount calculated for the quarter in which the price substitution takes effect.¹³ CMS also does not substitute prices when the Food and Drug Administration (FDA) has identified a drug as being in short supply.¹⁴ Price substitutions take effect in the quarter after OIG shares the

⁸ Section 1847A(b)(1) of the Act. Medicare beneficiaries are responsible for 20 percent of this amount in the form of coinsurance.

⁹ Part B claims dated on or after April 1, 2013, incur a reduction in payment in accordance with the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012 (see CMS Medicare FFS Provider e-News, Mandatory Payment Reductions in the Medicare Fee-for-Service (FFS) Program – "Sequestration," March 8, 2013). Under this mandatory payment reduction, Medicare's portion of the payment rate for most Part B drugs is reduced by 2 percent. This reduction does not apply to the coinsurance portion of the Medicare allowed amount for Part B drugs.

¹⁰ Section 1927(b)(3) of the Act.

¹¹ 42 CFR § 414.904(d)(3).

¹² Ibid.


¹³ Ibid.

¹⁴ Ibid.

results of its most recent pricing comparison and remain in effect for 1 quarter.¹⁵

Because of the 2-quarter lag between the ASP reporting period and the effective date of reimbursement amounts, and the additional quarter that is necessary for OIG to complete its pricing comparison, there is a 3-quarter lag between the ASP reporting period and the effective date of the price substitutions. As shown in Exhibit 2, price substitutions that took effect in

Exhibit 2: Timeline for AMP-Based Price Substitutions in 2016



the fourth quarter of 2016 were based on comparisons of ASPs and AMPs from the first quarter of 2016.

OIG Monitoring of ASPs and AMPs

To comply with its statutory mandate, OIG has provided CMS with pricing comparisons since the January 2005 implementation of the ASP reimbursement methodology for Part B drugs. OIG issued six annual reports for the years prior to CMS's April 2013 implementation of the AMP price-substitution policy. Only four of these reports calculated estimated savings. These four reports estimated that Medicare and its beneficiaries would have saved \$35 million from 2009 through 2012 if CMS had implemented the AMP price substitutions. OIG's 2013 annual report was the first to provide annual savings that were a direct result of CMS's price-substitution policy.

Methodology

To determine the effects of the price-substitution policy, we calculated the difference between ASP-based payment and AMP-based payment for each drug with a price substitution. We then applied this difference to the Medicare utilization for each of these drugs. To account for a 3-quarter lag between the reporting of pricing data and the application of price

¹⁵ Ibid.

substitutions, we used drug utilization data from the fourth quarter of 2016 through the third quarter of 2017 to calculate the savings based on 2016 ASP data. Appendix A provides a more detailed methodology.

Standards

This study was conducted in accordance with the *Quality Standards for Inspection and Evaluation* issued by the Council of the Inspectors General on Integrity and Efficiency.

FINDINGS

CMS's price-substitution policy saved Medicare and its beneficiaries \$13.1 million over 1 year

CMS initiated price substitutions for 16 drugs based on 2016 data. Price substitutions for these drugs saved Medicare and its beneficiaries \$13.1 million over the 1-year period between the fourth quarter of 2016 and the third quarter of 2017, as shown in Exhibit 4. Since CMS instituted its price-substitution policy in 2013, Medicare and its beneficiaries have saved \$55.4 million, including the \$13.1 million for 2016.

Exhibit 4: Price substitutions saved Medicare and its beneficiaries \$13.1 million

Drug	Description	Quarter(s) in Which Price Substitutions Occurred				Savings
		Fourth Quarter 2016	First Quarter 2017	Second Quarter 2017	Third Quarter 2017	
J0636	Calcitriol injection		✓			\$31
J0670	Mepivacaine HCl injection				✓	\$802
J0834	Cosyntropin cortrosyn injection		✓			\$2,816
J0878	Daptomycin injection			✓	✓	\$1,605,561
J1568	Octagam injection	✓	✓			\$5,292,644
J1570	Ganciclovir sodium injection	✓	✓	✓		\$89,282
J2400	Chloroprocaine HCl injection				✓	\$243
J2501	Paricalcitol		✓	✓	✓	\$477
J2700	Oxacillin sodium injection			✓		\$3,678
J7520	Sirolimus oral	✓	✓	✓	✓	\$5,967,216
J9178	Epirubicin HCl injection	✓	✓			\$5,640
J9190	Fluorouracil injection	✓	✓			\$92,260
J9200	Floxuridine injection	✓		✓	✓	\$638
J9209	Mesna injection		✓	✓		\$3,941
Q0166	Granisetron HCl oral	✓		✓		\$3,281
Q0167	Dronabinol oral	✓			✓	\$3,875
					Total	\$13,072,385

Source: OIG analysis of AP and AMP data from 2016

Expanding the price-substitution criteria could have generated up to \$2.7 million in additional savings for Medicare and its beneficiaries

CMS has maintained a cautious approach to price substitutions. However, this cautious approach may restrict the Government's ability to limit potentially excessive payment amounts based on ASPs. If CMS had expanded its price-substitution criteria to include certain other Part B drugs in 2016, Medicare and its beneficiaries could have saved up to an additional \$2.7 million over 1 year.

Millions could be saved by expanding the substitution criteria to include drugs that exceeded the 5-percent threshold in a single quarter. Nineteen drugs with complete AMP data exceeded this threshold in at least 1 quarter of 2016 but were not eligible for price substitution in that quarter because they did not meet CMS's duration criteria, i.e., did not exceed the threshold in the previous 2 quarters or 3 of the previous 4 quarters. If the 19 drugs had been eligible for price reductions on the basis of data from a single quarter only, Medicare and its beneficiaries could have saved up to an additional \$2.7 million between the fourth quarter of 2016 and the third quarter of 2017.¹⁶ Since 2014, Medicare and its beneficiaries could have saved up to an additional \$22.2 million, including the \$2.7 million for 2016, if CMS had expanded its criteria to include drugs that exceeded the 5-percent threshold in a single quarter.

Previously, CMS has expressed concern that price substitutions based on results from a single quarter may represent one aberrant quarter of pricing rather than a market trend.¹⁷ However, price discrepancies for over half of the 19 drugs do not appear to have resulted from isolated fluctuations. According to 2015 and 2016 data, 11 of these 19 drugs exceeded the 5-percent threshold more than once over the 2-year period.¹⁸ Specifically, 8 of the 19 exceeded the threshold in 2 of the 8 quarters, and another 3 drugs exceeded the threshold three or more times in the 8 quarters.

If CMS would prefer to employ a more cautious approach than substitution based on a single quarter of data, it could expand its price-substitution criteria to include drugs that exceed the 5-percent threshold in 2 of the previous 6 quarters. Under this approach, three drugs would have been eligible for price substitutions. Medicare and its beneficiaries could have saved an estimated \$64,000 on these three drugs.

¹⁶ These 19 drugs were not identified by FDA as being in short supply and did not have AMP-based substitution amounts that were greater than the ASP-based reimbursement amounts in the quarters during which the substitutions would have occurred. Three of these drugs did not have any allowed Part B utilization during the reviewed period; therefore, the estimated savings for these drugs was \$0.

¹⁷ 76 Fed. Reg. 73026, 73288 (Nov. 28, 2011).

¹⁸ This analysis is based on pricing comparison results for the 2-year period between the first quarter of 2015 and the last quarter of 2016.

CONCLUSION AND RECOMMENDATION

Under the current price-substitution policy, 16 drugs were subject to reimbursement reductions on the basis of data from 2016, saving Medicare and its beneficiaries \$13.1 million between the fourth quarter of 2016 and the third quarter of 2017. Since the inception of price substitution, Medicare and its beneficiaries have saved \$55.4 million. Thus, price substitution continues to be an important mechanism for CMS to employ in ensuring reasonable payments for Medicare Part B drugs.

CMS could achieve even greater savings for Medicare and its beneficiaries by expanding its criteria for AMP-based price substitutions. OIG has previously recommended that CMS expand the price-substitution criteria. Since 2014, Medicare and its beneficiaries could have saved up to an additional \$22.2 million if CMS had expanded its criteria. CMS stated that it did not concur with expanding the price-substitution policy and expressed concern that expanding price-substitution criteria may impede physician and beneficiary access to drugs. OIG agrees that access to prescription drugs should always be considered when contemplating pricing policies and supports current safeguards to prevent substitutions for drugs that FDA has identified as being in short supply. However, OIG continues to believe that CMS can achieve a better balance between safeguarding access to drugs and ensuring that Medicare and its beneficiaries do not overpay for drugs. To provide greater flexibility and achieve this continued balance, any future expansion of the payment substitution policy could contain a provision that would prevent a price substitution when there are indications that the substitution amount would be below provider acquisition costs.

Therefore, we continue to recommend that CMS:

Expand the price-substitution policy

To more effectively limit excessive payment amounts based on ASPs and to generate greater savings for Medicare and its beneficiaries, CMS should consider broadening its price-substitution criteria to include at least some additional drugs. A more expansive policy might include drugs with complete AMP data that exceed the 5-percent threshold in a single quarter. However, CMS also could consider a more modest expansion of the policy that better captures drugs that repeatedly exceed the threshold. For example, CMS could expand the criteria to include drugs with complete AMP data that exceed the 5-percent threshold in 2 of 6 quarters.

AGENCY COMMENTS AND OIG RESPONSE

CMS did not concur with our recommendation, instead stating that as additional data becomes available and as it continues to gain experience with the price-substitution policy, it will consider further changes as necessary. CMS believes the current policy safeguards—which identify drugs that exceed the 5-percent threshold for 2 consecutive quarters or 3 of 4 quarters—identify situations in which AMP consistently exceeds ASP.

OIG continues to believe that expanding the policy can achieve a balance between safeguarding access to drugs and ensuring that Medicare and its beneficiaries do not overpay for drugs. Our examination of 2016 data shows that if the policy had been expanded to include the 19 drugs that exceeded the 5-percent threshold in a single quarter, up to an additional \$2.7 million could have been saved by beneficiaries and the program. The majority of the 19 drugs we identified for these potential savings exceeded the threshold multiple times over a 2-year period. Expanding the policy to capture drugs that exceed the threshold in a single quarter could increase the savings to beneficiaries and the program and still ensure access to drugs.

To help ensure that CMS has sufficient information for its consideration regarding the price-substitution policy, OIG will continue to provide CMS with the results from our quarterly pricing comparisons, along with annual reports on the impact of the price-substitution policy.

For the full text of CMS’s comments, see Appendix B.

APPENDIX A: Detailed Methodology

We obtained NDC-level ASP data and AMP data for Part B drugs from CMS for 2016. We also obtained ASP-based reimbursement amounts and Part B drug utilization for the quarters in which price substitutions occurred, i.e., the fourth quarter of 2016 through the third quarter of 2017. In addition, we obtained the drugs that had price substitutions based on data from 2016.

For each quarter of 2016, we calculated the volume-weighted AMP for drugs in a manner consistent with CMS's methodology for calculating volume-weighted ASPs. We then compared the volume-weighted ASPs and AMPs and identified all drugs with ASPs that exceeded the AMPs by at least 5 percent. We also identified drugs that exceeded the 5-percent threshold but did not meet CMS's duration criteria for price substitution, i.e., they did not exceed the threshold in the previous 2 quarters or 3 of the previous 4 quarters.

To calculate the savings associated with price substitutions or potential price substitutions¹⁹ that could be made by expanding the policy, we first reduced AMP-based and ASP-based reimbursement amounts (103 percent of the volume-weighted AMP and 106 percent of the volume-weighted ASP, respectively) by the 2-percent reduction required by sequestration legislation. We then subtracted the AMP-based reimbursement amount from the ASP-based reimbursement amount for the quarter in which the price substitution occurred²⁰ and multiplied the difference by the Part B utilization for each drug in the respective quarter that the price substitution occurred.

Limitations

We did not verify the accuracy of manufacturer-reported ASP and AMP data, nor did we verify the underlying methodology used by manufacturers to calculate ASPs and AMPs. We also did not verify the accuracy of CMS's calculations of reimbursement amounts for Part B drugs.

Manufacturers are required to submit their quarterly ASP and AMP data to CMS within 30 days after the close of the quarter. We did not determine whether manufacturers provided any updated data to CMS at a later date.

¹⁹ There were two drugs that would have met the criteria to be included in our analysis of potential price substitutions. However, manufacturers subsequently provided CMS with revised AMPs and unit types for these drugs. As a result of these revisions, these drugs no longer met the criteria for inclusion in our analysis and we therefore removed them.

²⁰ AMP-based price substitutions based on data from the first through fourth quarters of 2016 were applied in the fourth quarter of 2016 through the third quarter of 2017, respectively.

APPENDIX B: Agency Comments




DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services

200 Independence Avenue SW
Washington, DC 20201

DATE: JUL -6 2018

TO: Daniel R. Levinson
Inspector General

FROM: Seema Verma 
Administrator

SUBJECT: Office of Inspector General (OIG) Draft Report: Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices (OEI-03-18-00120)

The Centers for Medicare & Medicaid Services (CMS) appreciates the opportunity to review and comment on the Office of Inspector General's (OIG) draft report.

The President and the Department of Health and Human Services (HHS) are committed to putting American patients first by addressing the rising cost of prescription drugs for the American consumer. Most recently, the Administration released a bold plan for lowering drug costs and reducing out of pocket expenses. This comprehensive blueprint, *American Patients First*, addresses many of the challenges and opportunities impacting American patients and consumers, and HHS has begun taking many of the actions outlined in the plan.

CMS strives to maximize the affordability and availability of drugs for Medicare beneficiaries while protecting taxpayer dollars, and the current average manufacturer price substitution policy is consistent with this goal. As the OIG notes in its report, CMS' price substitution policy saved Medicare and its beneficiaries an estimated \$13.1 million over a one-year period between the fourth quarter of 2016 and the third quarter of 2017 by reducing payment limits for 16 Healthcare Common Procedure Coding System billing codes.

OIG's recommendations and CMS' responses are below.

OIG Recommendation

The OIG recommends that CMS expand the price substitution policy to include additional drugs.

CMS Response

CMS non-concurs with OIG's recommendation. CMS appreciates the OIG's study and looks forward to evaluating additional data related to the potential expansion of the price substitution policy and taking it into consideration when developing plans for future rulemaking in this area. As additional data becomes available and CMS continues to gain experience with this policy, CMS will consider further changes as necessary.

CMS notes the current price substitution policy includes several safeguards finalized through rulemaking, including the requirement that the applicable threshold must be exceeded in two consecutive or three of four quarters. This safeguard is intended to identify situations where average manufacturer price consistently exceeds average sales price rather than using a single quarter of pricing, which may suggest one aberrant pricing quarter rather than a market trend. This also minimizes the potential risk of impacting access to medically necessary drugs. While CMS appreciates that OIG evaluated drugs exceeding the threshold from a single quarter for both 2015 and 2016, CMS maintains that more systematic data analysis beyond one quarter year over year is needed in order to evaluate trends and then further consider the recommendation.

ACKNOWLEDGMENTS

Conswelia McCourt served as the team leader for this study. Office of Evaluation and Inspections staff who provided support include Joe Chiarenzelli, Althea Hosein, Christine Moritz, and Meghan Riggs.

This report was prepared under the direction of Linda Ragone, Regional Inspector General for Evaluation and Inspections in the Philadelphia regional office, and Edward Burley, Deputy Regional Inspector General.

To obtain additional information concerning this report or to obtain copies, contact the Office of Public Affairs at Public.Affairs@oig.hhs.gov.

ABOUT THE OFFICE OF INSPECTOR GENERAL

The mission of the Office of Inspector General (OIG), as mandated by Public Law 95-452, as amended, is to protect the integrity of the Department of Health and Human Services (HHS) programs, as well as the health and welfare of beneficiaries served by those programs. This statutory mission is carried out through a nationwide network of audits, investigations, and inspections conducted by the following operating components:

Office of Audit Services

The Office of Audit Services (OAS) provides auditing services for HHS, either by conducting audits with its own audit resources or by overseeing audit work done by others. Audits examine the performance of HHS programs and/or its grantees and contractors in carrying out their respective responsibilities and are intended to provide independent assessments of HHS programs and operations. These assessments help reduce waste, abuse, and mismanagement and promote economy and efficiency throughout HHS.

Office of Evaluation and Inspections

The Office of Evaluation and Inspections (OEI) conducts national evaluations to provide HHS, Congress, and the public with timely, useful, and reliable information on significant issues. These evaluations focus on preventing fraud, waste, or abuse and promoting economy, efficiency, and effectiveness of departmental programs. To promote impact, OEI reports also present practical recommendations for improving program operations.

Office of Investigations

The Office of Investigations (OI) conducts criminal, civil, and administrative investigations of fraud and misconduct related to HHS programs, operations, and beneficiaries. With investigators working in all 50 States and the District of Columbia, OI utilizes its resources by actively coordinating with the Department of Justice and other Federal, State, and local law enforcement authorities. The investigative efforts of OI often lead to criminal convictions, administrative sanctions, and/or civil monetary penalties.

Office of Counsel to the Inspector General

The Office of Counsel to the Inspector General (OCIG) provides general legal services to OIG, rendering advice and opinions on HHS programs and operations and providing all legal support for OIG's internal operations. OCIG represents OIG in all civil and administrative fraud and abuse cases involving HHS programs, including False Claims Act, program exclusion, and civil monetary penalty cases. In connection with these cases, OCIG also negotiates and monitors corporate integrity agreements. OCIG renders advisory opinions, issues compliance program guidance, publishes fraud alerts, and provides other guidance to the health care industry concerning the anti-kickback statute and other OIG enforcement authorities.